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E-mailAbstract—There is no cure for osteoarthritis. Current drug delivery relies on systemic delivery or injections into the
joint. Because articular cartilage (AC) degeneration can be local and drug exposure outside the lesion can cause
adverse effects, localized drug delivery could permit new drug treatment strategies. We investigated whether intense
megahertz ultrasound (frequency: 1.138MHz, peak positive pressure: 2.7 MPa, Ispta: 5 W/cm
2, beamwidth: 5.7 mm
at 26 dB, duty cycle: 5%, pulse repetition frequency: 285 Hz, mechanical index: 1.1) can deliver agents into AC
without damaging it. Using ultrasound, we delivered a drug surrogate down to a depth corresponding to 53% depth
of the AC thickness without causing histologically detectable damage to the AC. Thismay be important because early
osteoarthritis typically exhibits histopathologic changes in the superficial AC. In conclusion, we identify intense
megahertz ultrasound as a technique that potentially enables localized non-destructive delivery of osteoarthritis
drugs or drug carriers into articular cartilage. (E-mail: heikki.nieminen@helsinki.fi)  2015 World Federation
for Ultrasound in Medicine & Biology.
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About 10% of men and 18% of women over 60 y of age
have osteoarthritis (OA) (Woolf and Pfleger 2003). It is
painful for the patient, limits mobility and reduces quality
of life. As there is no regenerative therapy for OA, the last
treatment option is usually a total joint replacement.
Research on development of disease-modifying OA
drugs has been active in recent decades (Pelletier and
Martel-Pelletier 2007). Currently available drug therapies
were developed under the limitation of poor localization,
that is, systemic delivery or injections into the joint. How-
ever, OA lesions in articular cartilage (AC) can be very
localized. Therefore, local administration of the drug
could potentially enhance the therapeutic effect within
the degenerated tissue while avoiding adverse effects
elsewhere in the body (Wieland et al. 2005). For instance,
although transforming growth factor TGF-b1 speeds up
AC matrix regeneration by stimulating chondrocytes, itddress correspondence to: Heikki J. Nieminen, Department of
s, University of Helsinki, POB 64, 00014 Helsinki, Finland.
: heikki.nieminen@helsinki.fi
2259simultaneously inflames the synovial capsule and
promotes osteophyte formation (Venkatesan et al.
2013). Non-destructive localized delivery of drugs into
AC could, therefore, lead to new treatment strategies
for OA therapy.
Small OA drug molecules such as glucosamine
(179 Da) and diacerein (368 Da) can move relatively
freely in and out of AC, resulting in short residence times.
On the other hand, penetration of large molecules ($45
kDa) into AC is limited (Maroudas 1976). A method to
force either large molecules (e.g., growth factors) or drug
carriers containing small drug molecules into AC could
contribute to localization and prolonged drug residence.
This would potentially confine drug exposure and permit
more personalized treatment than afforded by current
drug techniques of delivery into AC. Clinical techniques
to deliver drugs locally into AC are still to be developed,
but a few studies have already attempted to force agents
into AC by means of an electric field (Bajpayee et al.
2014), kilohertz ultrasound (Nieminen et al. 2012) and
acoustic shock waves (Nieminen et al. 2013).
High-intensity ultrasound (HIU) can transport mate-
rial through such phenomena as acoustic radiation force,
2260 Ultrasound in Medicine and Biology Volume 41, Number 8, 2015acoustic streaming and ultrasound–bubble interactions
(Ahmed et al. 2009; Dayton et al. 2002). All these
effects can potentially be harnessed to move agents
locally inside porous materials such as AC. It is known
that ultrasound can deliver agents into skin (Polat et al.
2011) and release encapsulated agents in tumor tissue
(Grull and Langereis 2012). We have previously reported
that low-frequency (20 kHz, 78 W/cm2) ultrasound can
deliver soot particles (in the nanometer to micrometer
range), models for drug carriers, locally into AC
(Nieminen et al. 2012). However, we observed microcra-
tering of the AC surface possibly caused by inertial cavi-
tation (Dalecki 2004). The risk of encountering this
adverse phenomenon can be avoided by increasing the
sonication frequency into the megahertz range. There-
fore, the aim of this study was to illustrate that intense
megahertz ultrasound enhances the penetration of a
kDa-sized agent into AC without damaging the tissue.METHODS
Samples
Bovine joints were obtained from a local meat refin-
ery (Lihakonttori Oy, Helsinki, Finland). Cylindrical os-
teochondral plugs (samples 1–5, n 5 5, diameter 5 28
mm) were prepared from normal-looking femoral con-
dyles, one sample per animal (Fig. 1). For damage assess-
ment tests, we prepared paired osteochondral strips
(samples 6–9[a, b], n 5 8, width 5 7 mm) from four
joints with visually normal femoral condyles.Ultrasound experiments and damage assessment
A custom-made 1.138-MHz focused ultrasound sys-
tem (Fig. 2) (peak positive and peak negative pressure,
along the acoustic axes, 63 mm from the sample
surface 5 2.70 6 0.06 and 1.18 6 0.01 MPa, respec-
tively; beam width 5 5.7 mm at 26 dB of maximum
peak pressure; Isptp 5 488 W/cm
2, Isppa 5 102 W/cm
2,
Ispta 5 5 W/cm
2; pulse repetition frequency 5 285 Hz;
cycles per pulse 5 200; duty cycle 5 5.0%; mechanical
index [MI] 5 1.1; immersion fluid/subchondral bone
temperature,33C) was used to deliver a drug surrogate
(X-ray contrast agent: 1% w/v phosphotungstic acid
[PTA], a negatively charged molecule, molecular
weight 5 2.88 kDa) into samples 1–5 as follows: First,
the focus of the ultrasound beam was positioned at the
AC surface; second, the sample was sonicated for 2.5 h.
The contrast agent was dissolved in 70% ethanol for sam-
ple 1 because PTA in ethanol is used to label collagen in
embryos (Metscher 2011). We chose phosphate-buffered
saline (PBS) as base medium for samples 2–5 to provide a
more physiologic-like environment.
For damage assessment (histopathologic assess-
ment), one sample (a) each from sample pairs 6–9 wassonicated in PBS containing no PTA using the protocol
described earlier (Fig. 1). The second sample (b) from
sample pairs 6–9 was immersed, but not exposed to ultra-
sound and acted as a paired control. Samples were then
subjected to histologic staining (Masson’s trichrome
and Safranin-O) to evaluate collagen and proteoglycan
distributions, respectively. To evaluate potential
ultrasound-induced damage to the AC, the excisions
were optically imaged at 103 using a light microscope
(Aristoplan, Ernst Leitz Wetzlar, Wetzlar, Germany)
and camera (MicroPublisher 5.0 RTV, Qimaging, Surrey,
BC, Canada), and at 13 using a microscope slide scanner
(Pathscan Enabler IV, Meyer Instruments, Houston, TX,
USA).
Ultrasound beam characteristics (peak positive/
negative pressure amplitude, MI, beam width and inten-
sity) were determined using a calibrated needle hydro-
phone (element diameter 5 0.2 mm, tip diameter 5
0.67 mm, Model HPM02/1, Precision Acoustics, Dor-
chester, UK). Intensity values (SPTP, SPPA, SPTA)
were determined in ion-exchanged water at a distance
from the transducer that corresponded to the position of
the AC surface.
Detection of delivery
Samples 1–5 were imaged with X-ray microtomog-
raphy (XMT) to determine PTA distribution within the
tissue (Nanotom 180 NF, Phoenix X-ray Systems/GE,
Fairfield, CT, USA; settings for sample 1: 75 kV, 190
mA, 1,080 projections, voxel side length5 38.0 mm; set-
tings for samples 2–5: 75–80 kV, 75–110 mA, 1,200 pro-
jections, voxel side length 5 16.3 to 16.7 mm). To avoid
sample drying during XMT, the samples were kept in
sealed containers containing cotton balls moistened
with the base solution (70% ethanol for sample 1 or
PBS for samples 2–5). The PTA distributions in AC
were determined on the basis of X-ray attenuation in
the XMT images. Raw data from samples presented in
Nieminen et al. (2013) (samples 1 and 2) were reanalyzed
and pooled into this study.
The penetration depth of PTA and thickness of AC
were determined from reconstructed XMT image stacks
(Fig. 3). AC without PTA (i.e., volume 1) and AC with
PTA (i.e., volume 2) were segmented from the XMT im-
age stack based on image contrast (Avizo Fire, Versions
7.1.1–8.0.1, FEI Visualization Sciences Group, Burling-
ton, MA, USA). The local thickness of each volume
was calculated with the LocalThickness plugin
(Dougherty and Kunzelmann 2007) to the ImageJ soft-
ware (Version 1.4.7, NIH, Bethesda, MD, USA), and pro-
jected onto a plane approximately tangential to the AC
surface with the VGStudioMAX software (Version 1.3,
Volume Graphics, Heidelberg, Germany). We named
this the spatial maximum penetration map (SMPM).
Fig. 1. Sample handling. Bovine articular cartilage samples were prepared for treatment (a) and for damage assessment
(b). Five osteochondral cylinders were sonicated with MHz ultrasound while immersed in phosphotungstic acid (PTA)1
70% ethanol (sample 1) or PTA 1 phosphate-buffered saline (PBS) (samples 2–5) (a) (Fig. 2). For damage assessment,
osteochondral tissue strips (width5 7 mm) were prepared from femoral condyle (b), one sample pair per joint. One sam-
ple from each joint was sonicated with megahertz ultrasound while immersed in PBS (samples 6a–9a) and the adjacent
samples (samples 6b–9b) not sonicated acted as controls. Damage assessment samples were subjected to histology that is,
Masson or Safranin-O staining and light microscopy.
US drug delivery into articular cartilage d H. J. NIEMINEN et al. 2261Within the SMPM of samples 2–5, the delivery depth
in the treatment area was defined as the mean 6 standard
deviation (SD) of the pixel values that were within 1-mm
radius from the sample center. The delivery depth into
adjacent tissue (control) was defined as the mean 6 SD
of pixel values that were inside a band 9.5–10.5 mm
from the sample center. In addition, the global maximum
of delivery depth within the SMPM was determined.RESULTS
After sonication, we observed increased X-ray atten-
uation (i.e., high PTA concentration) inside a circular
penetration shape at the location of the ultrasound beam
center in all samples (Fig. 4). For sample 1 (70% ethanol
as base medium), the maximum delivery depth was 488
6 15 mm (mean 6 SD), with no delivery in adjacent
Fig. 2. Experimental setup. The sample was immersed in a contrast agent (phosphotungstic acid [PTA]), while sonicated
with megahertz ultrasound. A thin nitrile-containing membrane prevented PTA penetration into the tissue from the side.
PBS 5 phosphate-buffered saline.
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39% of the AC thickness and was achieved at an average
penetration speed of 195 mm/h.
The delivery depths for samples 2–5 (immersed in
PTA 1 PBS solution while sonicated) are summarized
in Table 1 and Figures 4 and 5. For these samples, the
average penetration depth of PTA at the treatment area
was 2.6 times the penetration depth in the control
tissue (Fig. 5). For samples with strong PTA penetration
at the sample center, that is, samples 2, 3 and 5, the
maximum penetration depths were 775, 883 and 754
mm, respectively (Fig. 4), corresponding to a relative
penetration of 53 6 4% and an average penetration
speed of 322 mm/h. Sample 4 appeared to exhibit strong
passive PTA diffusion outside the ultrasound beam;
nevertheless, a circular PTA penetration pattern is seen
at the location of the ultrasound beam, that is, sample
center (Fig. 4f). Subchondral bone temperature re-
mained below 33C (n 5 3).Fig. 3. Image analysis of the delivery depth. Osteochondral cyl
icated with megahertz ultrasound were imaged using X-ray m
delivered PTAwas segmented out of articular cartilage based on
ary of the segmented volume). Spheres as large as possible in di
The maximum diameter values were projected on a plane parall
of the segmented volume in this projection. Thickness values (m
mm diameter represented the delivery depth within ultrasound b
mm band, from 9.5 to 10.5 mm relative to the sample center, rHistologic evaluation of ultrasound-treated AC sam-
ples (6a–9a) and control samples (6b–9b) revealed no dif-
ference between the groups with respect to superficial
tissue fibrillation or collagen (blue contrast in Masson’s
trichrome-stained sections) or proteoglycan (red contrast
in Safranin-O-stained sections) distribution (Fig. 6).DISCUSSION
The results suggest that intense megahertz ultra-
sound delivered the drug surrogate into AC. Because
the applied ultrasound energy (1 MHz, 2.7/1.2 MPa
peak positive/negative pressure amplitude at focus,
Isptp 5 488 W/cm
2, Isppa 5 102 W/cm
2, Ispta 5 5 W/
cm2) attenuates in soft tissue (Goss et al. 1979;
Nieminen et al. 2009) and body fluids (Narayana et al.
1984), it may induce acoustic radiation forces in solids
or at solid–fluid interfaces (Westervelt 1951) and fluid
streaming (Nyborg 1953), potentially contributing toinders immersed in phosphotungstic acid (PTA) and son-
icrotomography, producing a 3-D image stack (a). The
image contrast (b) (solid blue line represents the bound-
ameter were then placed inside the segmented volume (c).
el to the cartilage surface (c, d) representing the thickness
ean6 standard deviation) at the sample center within 1-
eam (treatment) (d), whereas thickness values within a 1-
epresented delivery depth by passive diffusion (control).
Fig. 4. Delivery outcome. Surrogate (phosphotungstic acid [PTA]) delivery was observed in X-ray microtomography
(XMT) images of samples 1–3 and 5 (a–e, g) at the sample center (location of maximum delivery depth indicated
with black arrow) compared with adjacent tissue (white arrow) after the sample was sonicated with intense megahertz
ultrasound in surrogate immersion. In sample 4 (f), diffusion (potentially passive) is strong outside the ultrasound
beam (purple arrow), but deeper delivery is seen at the sample center (blue arrow) compared with adjacent tissue (green
arrow). The result suggests that ultrasound can deliver agents into articular cartilage and that the delivery is confined to the
location of sonication.
US drug delivery into articular cartilage d H. J. NIEMINEN et al. 2263mass transfer into and inside articular cartilage. The radi-
ation pressure generated in water at the location of AC
surface is on average 680 Pa during one ultrasound
burst. The resulting radiation force and PRF correspond
to tapping the tissue 2.6 million times during the treat-
ment. Specifically, stable cavitation (threshold for unsta-
ble inertial cavitation 5 3.9 MPa peak negative pressure
at 1 MHz [American Institute of Ultrasound in Medicine
2008]) is one possible explanation for the delivery; that is,
ultrasound may excite micro- or nanobubbles to generate
a streaming fluid around the bubbles (Ahmed et al. 2009).
Such streaming could enhance the diffusion within the ul-
trasound beam. As we detected a temperature rise in the
subchondral bone from room temperature to 33C, it is
possible that the temperature increase in AC enhances
diffusion of delivered agents into and inside AC (Carsi
et al. 2004).
The PTA delivery depth was relatively similar in all
samples (excluding sample 4) and limited to a relatively
confined round region (Fig. 4f). The difference in deliv-Table 1. Penetration depth of PTA at the treatment location, the lo
samples immersed in PB
Sample
Treatment penetration
depth (mm)
Control penetration
depth (mm)
2 742 6 4 0 6 0
3 869 6 11 197 6 211
4 654 6 8 653 6 65
5 684 6 18 264 6 186
PBS 5 phosphate-buffered saline; PTA 5 phosphotungstic acid.
* The treatment location values were calculated as the mean6 standard devia
were calculated as the mean6 standard deviation within a 1-mm band at a radi
numbers of pixels used to calculate delivery depth statistics were 11,213–11,87
y Maximum located outside the sample center. The maximum value at samery can be due to biological variation, that is, perme-
ability, which can vary with the biochemical
composition of AC and from one joint to another. Perme-
ability affects the speed of passive diffusion. The base so-
lution was 70% ethanol for sample 1 and PBS for samples
2–5, which may impair the comparability of delivery in
sample 1 to delivery in samples 2–5. PTA is a negatively
charged molecule that is attracted by collagen. Therefore,
we expected to see PTA penetration into the control tis-
sue. Despite this, enhanced penetration at the sample cen-
ter was evident compared with adjacent tissue.
Qualitatively, no histologic difference was observed
in AC surface structure or in the content of collagen or
proteoglycan between sonicated and non-sonicated sam-
ples (Fig. 6). Because of the low MI (1.1), we presumed
that the exposure should be tolerable, as the MI does
not exceed the U.S. Food and Drug Administration-
defined maximum of 1.9 for clinical ultrasound imaging
(Dalecki 2004). Previously we used 20-kHz HIU
(Nieminen et al. 2012) to deliver particles intocation of the global maximum and the control location for all
S 1 PTA solution*
Penetration depth difference:
Treatment 2 Control (mm)
Maximum penetration
depth (mm)
742 775
672 883
1 734y (686)
420 754
tion of values within 1-mm radius from sample center. The control values
al distance of 10 mm (from 9.5 to 10.5 mm) from the sample center. The
3 and 183,662–202,668 for treatment and control, respectively.
ple center is provided in parentheses.
Fig. 5. Penetration depths. Penetration depths (mean6 standard
deviation) at sample center (treatment) compared with adjacent
tissue (control) (Fig. 3). The samples were immersed in phospho-
tungstic acid (PTA)1 phosphate-buffered saline (PBS) solution,
while sonicated with intense megahertz ultrasound.
Fig. 6. Damage assessment. Typical histologic sections for dam
no ultrasound exposure (right). We observed no difference in p
trichrome staining) distribution or fibrillation in superficial artic
that intense megahertz ultrasound did not induce
2264 Ultrasound in Medicine and Biology Volume 41, Number 8, 2015osteochondral tissue; however, this induced superficial
microcratering in the AC, because the pressure threshold
for inertial cavitation is much lower at 20 kHz (e.g., 68-
kPa peak negative pressure [PNP] at 23 kHz [Birkin
et al. 2005]) than at 1.138 MHz (3.9-MPa PNP at 1
MHz [American Institute of Ultrasound in Medicine
2008]). Absence of evident damage to the AC, therefore,
suggests that megahertz ultrasound may be a preferable
approach for drug delivery compared with kilohertz fre-
quency ultrasound.
In humans, delivering PTA halfway through the
cartilage thickness is potentially important, because early
OA typically manifests as histopathologic changes (su-
perficial fibrillation and clefts, loss in proteoglycans) in
the superficial AC (Pritzker et al. 2006). The average de-
livery speed of the agent in this study, 5 mm/min, sug-
gests that agent delivery to the very superficial articular
cartilage can be achieved with the proposed technique
within a clinically acceptable time frame (on averageage assessment samples: ultrasound exposure (left) and
roteoglycan (Safranin-O staining) or collagen (Masson’s
ular cartilage between the different groups. This suggests
evident damage to the articular cartilage.
US drug delivery into articular cartilage d H. J. NIEMINEN et al. 2265an50 mm penetration depth in 10 min for a molecule or
drug carrier equivalent to PTA). With respect to delivery
of agent into deeper tissue, the delivery speed is currently
too low for clinical relevance. In addition, bovine carti-
lage properties in vitro may differ significantly from hu-
man cartilage properties in vivo. Although the control
tissue (sample edge) is less than one-third of the 26 dB
beam width of the ultrasound, control tissue may have
been subjected to ultrasound exposure and acoustic
streaming affecting the control. Despite these limitations,
the results are encouraging, with successful delivery
without apparent damage. Further research is needed to
identify the mechanisms of delivery, to enhance delivery
speed, to confirm cell viability and to test the biological
response of the proposed approach using OA drugs.
The proposed experimental setup was designed to
study the capability of megahertz ultrasound to transport
agents into articular cartilage. The technical realization of
the potential clinical application could, however, differ
significantly from that used in this study. Delivery with
megahertz ultrasound could be applied not only extracor-
poreally, but also intra-articularly. An intra-articular
approach would allow local administration of the drug
or drug carrier enhanced by ultrasonic delivery. Examples
of intra-articular approaches could be a catheter-based
high-intensity focused transducer or a fiber optic photo-
acoustic ultrasound system, which because of their small
size could fit into the joint cavity.CONCLUSIONS
We have illustrated the ability of intense megahertz
ultrasound to transport agents into articular cartilage
without causing microscopically discernible histologic
damage. Ultrasound, therefore, has the potential to
deliver agents such as drugs and drug carriers into artic-
ular cartilage in a localized manner. At best, this approach
could permit new treatment strategies for OA drug ther-
apy and a paradigm shift in drug development of locally
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